Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

New England Journal of Medicine

Volumn 351, Issue 15, 2004, Pages 1502-1512

  Tannock, Ian F ^a,m   De Wit, Ronald ^b   Berry, William R ^c   Horti, Jozsef ^d   Pluzanska, Anna ^e   Chi, Kim N ^f   Oudard, Stephane ^g   Théodore, Christine ^h   James, Nicholas D ⁱ   Turesson, Ingela ^j   Rosenthal, Mark A ^k   Eisenberger, Mario A ^l  

^a UNIVERSITY OF TORONTO   (Canada)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Raleigh Hematology Oncology Associates   (United States)

^d NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^j UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^k Cancer Trials Australia   (Australia)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m PRINCESS MARGARET HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; MORPHINE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; LACRIMAL GLAND DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SENSORY NEUROPATHY; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISONE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TAXOIDS;

EID: 4744366279     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa040720     Document Type: Article

References (29)

1. American Cancer Society (ACS). Cancer facts & figures 2003. (Accessed September 13, 2004, at http://www.cancer.org/docroot/STT/stt_0_2003.asp? sitearea=STT&level=1.)
2. Oades GM, Coxon J, Colston KW. The potential role of bisphosphonates in prostate cancer. Prostate Cancer Prostatic Dis 2002;5:264-72.
3. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
4. Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MKC PK05 Trial). J Natl Cancer Inst 2003;95:1300-11.
5. Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European Organization for Research and Treatment of Cancer genitourinary group. J Clin Oncol 2001;19:62-71.
6. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989;7:590-7.
7. Martel CL, Gumerlock PH, Meyers FJ, Lara PN Jr. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003;29:171-87.
8. Osoba D, Tannok IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654-63.
9. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
10. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168:2439-43.
11. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17:2506-13.
12. Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone refractory prostate cancer and pain. J Clin Oncol 2003;21:3335-42.
13. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001;12:1273-9.
14. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001;28:Suppl 15:8-15.
15. Friedland D, Cohen J, Miller R Jr, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999;26:Suppl 17:19-23.
16. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26:Suppl 17:14-8.
17. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 2001;19:2509-16.
18. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 2002;20:Suppl 1:31-5.
19. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003;21:123-8.
20. Chen TT, Chute JP, Feigal E, Johnson BE, Simon R. A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst 2000;92:1601-7.
21. Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes: pathophysiology and clinical significance. Urol Clin North Am 1997;24:421-31.
22. Wirth MP, Froschermaier SE. The anti-androgen withdrawal syndrome. Urol Res 1997;25:Suppl 2:S67-S71.
23. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277-99.
24. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument. Urology 1997;50:920-8.
25. Kornblith AB, Herndon JE II, Zuckerman E, Godley PA, Savarese D, Vogelzang NJ. The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol 2001;12:633-41.
26. WHO criteria. In: WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979. (Offset publication no. 48.)
27. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
28. Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000;18:1440-50.
29. Weitzman AL, Shelton G, Zuech N, et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 2000;163:834-7.